Trial · NCT07045142
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142, Phase 3, Recruiting, Central South University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients. Trials, record NCT07045142. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07045142
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
- NCT number
- NCT07045142
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Central South University
- Conditions
- Schizophrenia
- Interventions
- Atorvastatin, Metformin, Placebo
- First posted
- 2025-07-01
- Last updated
- 2026-08-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Fasting Blood Glucose Concentration | Baseline, 3rd month, 6th month | |
| Primary | Change from Baseline in Glycated Hemoglobin (HbA1c) Concentration | Baseline, 3rd month, 6th month | |
| Primary | Oral Glucose Tolerance Test | Baseline, 3rd month, 6th month | The Oral Glucose Tolerance Test (OGTT) requires subjects to undergo an 8-hour fasting period, followed by an initial measurement of fasting blood glucose via a portable glucometer using a finger prick. Subsequently, subjects are instructed to consume a solution containing 75 grams of anhydrous glucose dissolved in 300 milliliters of water. Blood samples are then collected through finger pricking at 1 hour and 2 hours post-ingestion for further analysis of glucose levels. |
| Secondary | Change from Baseline in Fasting insulin Concentration | Baseline, 3rd month, 6th month | |
| Secondary | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) | Baseline, 3rd month, 6th month | HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is a recognized method for estimating insulin resistance, which plays a critical role in metabolic disorders such as type 2 diabetes and cardiovascular disease. This assessment requires fasting for at least eight hours, followed by the measurement of fasting insulin and fasting glucose levels from blood samples. The HOMA-IR value indicates the degree of insulin resistance; higher values suggest reduced cellular responsiveness to insulin, thereby correlating with increased risk for metabolic syndrome and type 2 diabetes. |
| Secondary | Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score | Baseline, 3rd month, 6th month | Range: 30 to 210; Higher Scores Indicate Worse Symptoms. |
| Secondary | Change from Baseline in Global Assessment of Functioning Scale (GAF) Total Score | Baseline, 3rd month, 6th month | Range: 0 to 100; Higher Scores Indicate Better Functioning. |
| Secondary | Abdominal ultrasound examination. | baseline, 6 months | Abdominal ultrasound is performed only at designated study sites and serves as a secondary outcome.The abdominal ultrasound examination will focus on assessing the occurrence of metabolic associated fatty liver disease (MAFLD). Subjects are required to fast for at least 8 hours prior to the examination, and they will lie supine on the examination table. After applying a coupling agent, an ultrasound scan will be performed. The physician will measure the size of the liver, observe its echo characteristics, and assess the echo differences with surrounding organs to determine the presence of liver enlargement or fat deposition. MAFLD typically presents as increased hepatic echogenicity and blurred liver margins. Doppler ultrasound may also be used to evaluate hepatic blood flow if necessary. All examination results will be recorded on case report forms for comprehensive analysis to assess the metabolic status and the degree of MAFLD in the study subjects. |
| Secondary | Glycated Albumin (GA) | Baseline, 3rd month, 6th month |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07045142
GET https://conductscience.org/api/trials/v1/NCT07045142/registered